• Molecular NameRabeprazole
  • SynonymIrsogladine Maleate; rabeprazole sodium; Rebeprazole sodium
  • Weight359.45
  • Drugbank_IDDB01129
  • ACS_NO117976-89-3
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)2.48
  • pka5
  • LogD (pH=7, predicted)2.47
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.74
  • LogSw (predicted, AB/LogsW2.0)0.32
  • Sw (mg/ml) (predicted, ACD/Labs)0.06
  • No.of HBond Donors1
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds8
  • TPSA96.31
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn antiulcer drug in the class of proton pump inhibitors.
  • Absorption_value90.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability52.0
  • Protein binding96.3
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMostly non-enzymatic, partly hepatic (CYP2C19)
  • Half life1~2 h
  • Excretion90% renal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe most common side effects of Rabeprazole are diarrhea, nausea, vomiting, constipation, rash and headaches. Dizziness, nervousness, abnormal heartbeat, muscle pain, weakness, leg cramps and water retention rarely occur.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A